Home page Home page
AstraZeneca

Vaxxitek HVT+IBD
Infectious bursal disease and Marek’s disease vaccine (live recombinant)


PACKAGE LEAFLET

Vaxxitek HVT+IBD suspension and solvent for suspension for injection


  1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT


    Marketing authorisation holder Boehringer Ingelheim Vetmedica GmbH 55216 Ingelheim/Rhein

    Germany


    Manufacturer responsible for batch release Boehringer Ingelheim Animal Health France SCS Laboratoire Porte des Alpes

    Rue de l’Aviation 69800 Saint-Priest France


  2. NAME OF THE VETERINARY MEDICINAL PRODUCT


    Vaxxitek HVT+IBD Suspension and solvent for suspension for injection


  3. STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S)

    Each dose of vaccine contains: Active ingredient:

    Live vHVT013-69 recombinant virus, at least ....................................................... 3.6 to 4.4 log10 PFU* Excipient......................................................................................................................................qs 1 dose


    Diluent:

    Diluent.........................................................................................................................................qs 1 dose


    *Plaque forming unit


  4. INDICATION(S)


    For active immunisation of chickens:


    • To prevent mortality and to reduce clinical signs and lesions of Infectious Bursal disease.

      The onset of protection is from 2 weeks and the protection extends to 9 weeks.

    • To reduce mortality, clinical signs and lesions of Marek’s disease.

      The onset of protection is from 4 days. A single vaccination is sufficient to provide protection during the risk period.


  5. CONTRAINDICATIONS


    Do not use in birds in lay and breeding birds.

  6. ADVERSE REACTIONS


    None known.

    If you notice any serious effects or other effects not mentioned in this package leaflet, please inform your veterinary surgeon.


  7. TARGET SPECIES


    Day-old chickens and 18 days embryonated eggs.


  8. DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION


    Subcutaneous or in ovo route.


    For in ovo administration, an automated egg injection machine can be used. The device should be proven to safely and effectively deliver the appropriate dose. The instructions for use of this device should be strictly followed.


    Subcutaneous route: one single injection of 0.2 ml per chicken at the age of one day.


    In ovo route: one single injection of 0.05 ml per egg at 18 days of embryonation.


  9. ADVICE ON CORRECT ADMINISTRATION


    • Wear protective gloves and spectacles during the ampoule thawing and opening operations.

    • Remove from the liquid nitrogen container only those ampoules which are to be used immediately. When this product is mixed with Marek’s disease vaccine containing either Rispens (CVI988) strain or RN1250 strain, both should be diluted in the same solvent bag.

    • Thaw rapidly the contents of the ampoules by agitation in water at 25°C-30°C. Proceed immediately to next step.

    • As soon as they are thawed, open ampoules holding them at arm’s length in order to prevent any risk of injury should an ampoule break.

    • Once the ampoule is opened, draw up the contents into a 5 ml sterile syringe.

    • Transfer the suspension into the diluent (Do not use if cloudy).

    • Draw up 2 ml of the contents of the diluent into the syringe.

    • Rinse the ampoule with these 2 ml and then transfer the rinsing liquid into the diluent. Repeat the rinsing operation once or twice.

    • Repeat the thawing, opening, transfer and rinsing operations for the appropriate number of ampoules to be reconstituted in the diluent; either 1 ampoule of 1,000 doses of vaccine per 200 ml of diluent (or 1 ampoule of 2,000 doses of vaccine per 400 ml of diluent) for

      subcutaneous administration, or 4 ampoules of 1,000 doses of vaccine per 200 ml of diluent (or 4 ampoules of 2,000 doses of vaccine per 400 ml of diluent) for in ovo administration.

    • The diluted vaccine prepared as described is mixed by gentle agitation so as to be ready for use.

    It should be used immediately after the preparation (all of the diluted vaccine should be used up within one hour). This is why the vaccine suspension should only be prepared as and when

    required


  10. WITHDRAWAL PERIOD(S)


    Zero days.

  11. SPECIAL STORAGE PRECAUTIONS


    Keep out of the sight and reach of children. Store the vaccine in liquid nitrogen.

    Do not use after the expiry date stated on the ampoule.

    Shelf life of the reconstituted vaccine: up to 2 hours at a temperature below 25°C.


  12. SPECIAL WARNING(S)


    Special precautions for each target species: Vaccinate only healthy birds.


    Special precautions for use in animals:

    Apply the usual aseptic precautions to all administration procedures.

    As a live vaccine, the vaccine strain is excreted from vaccinated birds and may spread to turkeys. Safety and reversion to virulence trials have shown that the strain is safe for turkeys. However, precautionary measures have to be followed in order to avoid direct or indirect contact between vaccinated chickens and turkeys.


    Special precautions to be taken by the person administering the veterinary medicinal product to animals:

    Wear protective gloves and spectacles during the ampoule thawing and opening operations.

    Open ampoules holding them at arm’s length in order to prevent any risk of injury should an ampoule break.


    Lay:

    Do not use in breeding birds and birds in lay.


    Interaction with other medicinal products and other forms of interaction:


    For subcutaneous route:

    Safety and efficacy data are available which demonstrate that this vaccine can be mixed with Boehringer Ingelheim attenuated vaccines against Marek’s disease containing either Rispens (CVI988) strain or RN1250 strain. Chickens with maternally derived antibodies against MD, when vaccinated with the mixed products, may have a delayed onset of immunity against infectious bursal disease.


    Safety and efficacy data are available which demonstrate that this vaccine can be administered on the same day but not mixed with Boehringer Ingelheim attenuated vaccines against Newcastle disease and Infectious bronchitis.

    No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product except the products mentioned above. A decision to use this vaccine

    before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.


    For in ovo route:

    In the absence of specific studies, no other veterinary medicinal product should be administered concurrently with the product.


    Use sterile and antiseptic-free and/or disinfectant-free equipment for injections purposes.

    Do not mix with any other veterinary medicinal product except those mentioned in the above paragraph and the diluent supplied for use with the product.

  13. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS, IF ANY


    Discard any ampoules that have been accidentally thawed. Do not re-freeze under any circumstances. Do not re-use opened containers of diluted vaccine.

    Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.


  14. DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED


    .


  15. OTHER INFORMATION


Live recombinant vaccine against Infectious Bursal Disease and Marek’s Disease.


The vaccine strain is a recombinant Herpesvirus of turkeys (HVT) expressing the protective antigen (VP2) of the Infectious Bursal Disease Virus (IBDV) strain Faragher 52/70.

The vaccine induces an active immunity and a serological response against Infectious Bursal Disease and Marek’s Disease in chickens.


1600 ml, 1800 ml or 2400 ml of diluent


Not all pack sizes may be marketed.


Veterinary medicinal product subject to prescription.